Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001422848-25-000111
Filing Date
2025-05-13
Accepted
2025-05-13 11:44:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5673
  Complete submission text file 0001422848-25-000111.txt   7365
Mailing Address 333 SOUTH HOPE STREET 55TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH HOPE STREET 55TH FLOOR LOS ANGELES CA 90071 213-486-9200
Capital World Investors (Filed by) CIK: 0001422849 (see all company filings)

EIN.: 951411037 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13G

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90685 | Film No.: 25938260
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)